We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Point-Of-Care Test Kit for Procalcitonin Evaluated

By LabMedica International staff writers
Posted on 25 Jan 2017
Print article
Image: The ABSOGEN PCT assay: control line (C) and test line (T) of the semi-quantitative kit for the procalcitonin analysis. Negative (
Image: The ABSOGEN PCT assay: control line (C) and test line (T) of the semi-quantitative kit for the procalcitonin analysis. Negative (
In response to inflammation, procalcitonin plasma concentrations increase more rapidly than other acute-phase reactants and higher values are associated with severe disease. Procalcitonin measurements assist in determining whether antibiotic therapy should be used.

For rapid diagnosis, point-of- Care test (POCT) is performed for early decision-making about additional testing or therapy. Despite being semi-quantitative, POCT results are helpful in situations when quantitative measurements are required quickly, such as within one to three hours.

Scientists at the Catholic University of Korea and their colleagues evaluated a total of 158 specimens, 115 specimens with procalcitonin levels ranging from 0 to 18.96 ng/mL were randomly selected for this study. Ages ranged from 15 to 90 years, with 51.7±19.9 (age mean ± SD) for the 158 samples, 77 males (54.4±19.9), and 81 females (49.1±19.4).

The team used the ABSOGEN PCT, which is a novel, rapid, and semi-quantitative immunochromatographic POCT assay that analyses whole blood. The study compared patient quantitative test results using the Modular E170 analyzer to ABSOGEN PCT test results. ABSOGEN PCT Analysis was performed using fresh whole blood sample remnants collected in EDTA tubes for routine complete blood count assays.

The investigators found that the concordance rate between ABSOGEN PCT using the reader and quantitative assay, between ABSOGEN PCT using naked eyes and quantitative assay and between ABSOGEN PCT using the reader and naked eyes for the same category was 83.5%, 78.5%, and 82.3%, respectively. The concordance rates for the ±1 categories were all 100%. Since high procalcitonin levels indicate the immediate need for sepsis therapy, a bedside test that yields results quickly can be critically important. In this situation, the present novel POCT could be useful.

The authors concluded that The ABSOGEN PCT blood procalcitonin test is a very simple and rapid test. The turnaround time is rapid because it uses whole blood; centrifugation is not required and the reaction is rapid. Serum or plasma also can be used. Sample volume for the test is small and no need for dilution. Even though the reaction band is narrow and faint, there is no difficulty in differentiating positive and negative, but some effort is needed to differentiate the grades using the naked eye and therefore a reader is recommended. The study was published on December 13, 2016, in the Journal of Clinical Laboratory Analysis.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Molecular Diagnostics

view channel
Image: A massive study has identified new biomarkers for renal cancer subtypes, improving diagnosis and treatment (Photo courtesy of Jessica Johnson)

Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes

Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more